| scholarly article | Q13442814 |
| review article | Q7318358 |
| systematic review | Q1504425 |
| P2093 | author name string | Mary E Rinella | |
| P433 | issue | 22 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | liver disease | Q929737 |
| fatty liver disease | Q6058862 | ||
| systematic review | Q1504425 | ||
| metabolic dysfunction–associated steatotic liver disease | Q1546498 | ||
| P304 | page(s) | 2263-73 | |
| P577 | publication date | 2015-06-09 | |
| P1433 | published in | The Journal of the American Medical Association | Q1470970 |
| P1476 | title | Nonalcoholic fatty liver disease: a systematic review | |
| P478 | volume | 313 |
| Q49974962 | 3-Acetyl-oleanolic acid ameliorates non-alcoholic fatty liver disease in high fat diet-treated rats by activating AMPK-related pathways. |
| Q55255755 | A Case-control Study to Evaluate the Prevalence of Nonalcoholic Fatty Liver Disease Among Patients with Moderate-to-severe Psoriasis. |
| Q64096895 | A Pathophysiological Model of Non-Alcoholic Fatty Liver Disease Using Precision-Cut Liver Slices |
| Q92856311 | A Systematic Review of NAFLD-Associated Extrahepatic Disorders in Youths |
| Q93190739 | A Therapeutic Silencing RNA Targeting Hepatocyte TAZ Prevents and Reverses Fibrosis in Nonalcoholic Steatohepatitis in Mice |
| Q57117681 | A Young Man with Non-alcoholic Steatohepatitis and Serum Anti-mitochondrial Antibody Positivity: A Case Report |
| Q37571422 | A critical role for ChREBP-mediated FGF21 secretion in hepatic fructose metabolism. |
| Q31171499 | A multi-component classifier for nonalcoholic fatty liver disease (NAFLD) based on genomic, proteomic, and phenomic data domains |
| Q90442272 | A network pharmacology-based approach to explore the effects of Chaihu Shugan powder on a non-alcoholic fatty liver rat model through nuclear receptors |
| Q91063272 | A pilot study of the effect of phospholipid curcumin on serum metabolomic profile in patients with non-alcoholic fatty liver disease: a randomized, double-blind, placebo-controlled trial |
| Q52651775 | A randomised, double-blind, placebo-controlled phase 1 study of the safety, tolerability and pharmacodynamics of volixibat in overweight and obese but otherwise healthy adults: implications for treatment of non-alcoholic steatohepatitis. |
| Q47555438 | A simple clinical model predicts incident hepatic steatosis in a community-based cohort: The Framingham Heart Study. |
| Q47618652 | AFAP1-AS1: A novel oncogenic long non-coding RNA in human cancers |
| Q42000401 | AMPK: a novel target for treating hepatic fibrosis |
| Q40722349 | APOC3 rs2070666 Is Associated with the Hepatic Steatosis Independently of PNPLA3 rs738409 in Chinese Han Patients with Nonalcoholic Fatty Liver Diseases |
| Q46029063 | Aberrant hepatic lipid storage and metabolism in canine portosystemic shunts. |
| Q99551752 | Abnormal metabolic processes involved in the pathogenesis of non-alcoholic fatty liver disease (Review) |
| Q38374046 | Absorption, Distribution, Metabolism, and Excretion of [(14)C]-Volixibat in Healthy Men: Phase 1 Open-Label Study. |
| Q52652698 | Active Coping and Perceived Social Support Mediate the Relationship Between Physical Health and Resilience in Liver Transplant Candidates. |
| Q37529340 | Acylated and desacyl ghrelin are associated with hepatic lipogenesis, β-oxidation and autophagy: role in NAFLD amelioration after sleeve gastrectomy in obese rats. |
| Q90663594 | Adaptive immunity: an emerging player in the progression of NAFLD |
| Q50206048 | Adiponectin deficiency rescues high-fat diet-induced hepatic injury, apoptosis and autophagy loss despite persistent steatosis |
| Q38777796 | Adiponectin regulates aquaglyceroporin expression in hepatic stellate cells altering their functional state. |
| Q61443409 | Adiposity in relation to risks of fatty liver, cirrhosis and liver cancer: a prospective study of 0.5 million Chinese adults |
| Q37588703 | Advanced Hepatic Fibrosis in Fatty Liver Disease Linked to Hyperplastic Colonic Polyp. |
| Q33840930 | Alcohol Consumption in Concomitant Liver Disease: How Much is Too Much? |
| Q36930189 | Alcohol produces distinct hepatic lipidome and eicosanoid signature in lean and obese |
| Q47609771 | An Overview of Dietary Interventions and Strategies to Optimize the Management of Non-Alcoholic Fatty Liver Disease. |
| Q98178483 | An Overview of Lipid Metabolism and Nonalcoholic Fatty Liver Disease |
| Q37448127 | An engineered FGF21 variant, LY2405319, can prevent non-alcoholic steatohepatitis by enhancing hepatic mitochondrial function |
| Q55323878 | Analogy between non-alcoholic steatohepatitis (NASH) and hypertension: a stepwise patient-tailored approach for NASH treatment. |
| Q47265706 | Angiopoietin-like protein 8/betatrophin correlates with hepatocellular lipid content independent of insulin resistance in non-alcoholic fatty liver disease patients. |
| Q92351098 | Anti-Obesity Effect of Standardized Extract of Microalga Phaeodactylum tricornutum Containing Fucoxanthin |
| Q92701842 | Antioxidant Versus Pro-Apoptotic Effects of Mushroom-Enriched Diets on Mitochondria in Liver Disease |
| Q52350739 | Aortic carboxypeptidase-like protein, a WNT ligand, exacerbates nonalcoholic steatohepatitis. |
| Q94570307 | Applications and Limitations of Noninvasive Methods for Evaluating Hepatic Fibrosis in Patients With Nonalcoholic Fatty Liver Disease |
| Q41962614 | Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update |
| Q35908245 | Association between Dietary Vitamin C Intake and Non-Alcoholic Fatty Liver Disease: A Cross-Sectional Study among Middle-Aged and Older Adults |
| Q64077826 | Association between Helicobacter pylori infection and non-alcoholic fatty liver disease in North Chinese: a cross-sectional study |
| Q37154805 | Association between bilirubin and risk of Non-Alcoholic Fatty Liver Disease based on a prospective cohort study |
| Q92088421 | Association between dietary sodium intake and non-alcoholic fatty liver disease in the US population |
| Q57930167 | Association between nonalcoholic fatty liver disease and subclinical atherosclerosis: a cross-sectional study on population over 40 years old |
| Q47559184 | Association between obstructive sleep apnea and non-alcoholic fatty liver disease: a systematic review and meta-analysis |
| Q41078413 | Association between physical activity and risk of nonalcoholic fatty liver disease: a meta-analysis. |
| Q38808650 | Association between plasminogen activator inhibitor-1 and severity of liver injury and cardiovascular risk in children with non-alcoholic fatty liver disease |
| Q89851343 | Association between plasminogen activator inhibitor-1 in young adulthood and nonalcoholic fatty liver disease in midlife: CARDIA |
| Q47872313 | Association between sleep condition and arterial stiffness in Chinese adult with nonalcoholic fatty liver disease |
| Q58109175 | Association of Pre-Transplant Renal Function with Liver Graft and Patient Survival after Liver Transplantation in Patients with Nonalcoholic Steatohepatitis |
| Q57066189 | Association of glycated hemoglobin with the risk of advanced fibrosis in non-alcoholic fatty liver disease patients without diabetes |
| Q36334120 | Association of leukocyte cell-derived chemotaxin 2 (LECT2) with NAFLD, metabolic syndrome, and atherosclerosis |
| Q89417346 | Association of γ-Glutamyltransferase with Atherosclerosis |
| Q37285741 | Associations between Dietary Nutrient Intakes and Hepatic Lipid Contents in NAFLD Patients Quantified by ¹H-MRS and Dual-Echo MRI. |
| Q90171100 | Associations of visceral fat thickness and anthropometric measurements with non-alcoholic fatty liver disease development in male patients mono-infected with human immunodeficiency virus |
| Q33890341 | Asymptomatic Meibomian Gland Dysfunction and Cardiovascular Disease Risk Factors in a Middle-Aged Population in Taiwan - A Cross-sectional Analysis |
| Q50931849 | Attenuation of hepatic steatosis by purple sweet potato colour is associated with blocking Src/ERK/C/EBPβ signalling in high-fat-diet-treated mice. |
| Q91304675 | Attributable Fractions of NAFLD for Mortality in the United States: Results From NHANES III With 27 Years of Follow-up |
| Q39024897 | Autophagy in chronic liver diseases: the two faces of Janus |
| Q94585668 | Bariatric and metabolic surgery during and after the COVID-19 pandemic: DSS recommendations for management of surgical candidates and postoperative patients and prioritisation of access to surgery |
| Q37443840 | Bibliometric analysis of top 100 cited articles in nonalcoholic fatty liver disease research. |
| Q89843712 | Biochemical and imaging parameters in acid sphingomyelinase deficiency: Potential utility as biomarkers |
| Q60302074 | Bioinformatics analysis of key differentially expressed genes in non-alcoholic fatty liver disease mice models |
| Q42286045 | Blood-derived macrophages prone to accumulate lysosomal lipids trigger oxLDL-dependent murine hepatic inflammation |
| Q41992691 | Body mass index trajectories in young adulthood predict non-alcoholic fatty liver disease in middle age: The CARDIA cohort study |
| Q92837793 | Bone marrow-derived macrophage contributes to fibrosing steatohepatitis through activating hepatic stellate cells |
| Q58699273 | C-peptide as a key risk factor for non-alcoholic fatty liver disease in the United States population |
| Q48103374 | Canagliflozin, an SGLT2 inhibitor, attenuates the development of hepatocellular carcinoma in a mouse model of human NASH. |
| Q95265626 | Catalpol Attenuates Hepatic Steatosis by Regulating Lipid Metabolism via AMP-Activated Protein Kinase Activation |
| Q92244423 | Catching Lipid Droplet Contacts by Proteomics |
| Q41483722 | Ccdc3: A New P63 Target Involved in Regulation Of Liver Lipid Metabolism. |
| Q36291704 | Characterisation of liver fat in the UK Biobank cohort. |
| Q41172019 | Characterization of the Cytochrome P450 epoxyeicosanoid pathway in non-alcoholic steatohepatitis |
| Q36118455 | Chemical Shift magnetization transfer magnetic resonance imaging |
| Q92504230 | Chinese Herbal Medicine Formula Shenling Baizhu San Ameliorates High-Fat Diet-Induced NAFLD in Rats by Modulating Hepatic MicroRNA Expression Profiles |
| Q51249709 | Circulating levels of miR-122 and nonalcoholic fatty liver disease in pre-pubertal obese children. |
| Q40214331 | Cirrhosis Patients with Nonalcoholic Steatohepatitis Are Significantly Less Likely to Receive Surveillance for Hepatocellular Carcinoma |
| Q104072633 | Clinical Feasibility of Quantitative Ultrasound Imaging for Suspected Hepatic Steatosis: Intra- and Inter-examiner Reliability and Correlation with Controlled Attenuation Parameter |
| Q47136445 | Clinical epidemiology and disease burden of nonalcoholic fatty liver disease |
| Q48127172 | Clinical risk scoring for predicting non-alcoholic fatty liver disease in metabolic syndrome patients (NAFLD-MS score). |
| Q51176303 | Clostridium butyricum B1 alleviates high-fat diet-induced steatohepatitis in mice via enterohepatic immunoregulation. |
| Q33712066 | Cocaine Use and Liver Disease are Associated with All-Cause Mortality in the Miami Adult Studies in HIV (MASH) Cohort |
| Q47113983 | Collagen I promotes hepatocellular carcinoma cell proliferation by regulating integrin β1/FAK signaling pathway in nonalcoholic fatty liver |
| Q89065358 | Combined effects of synbiotic and sitagliptin versus sitagliptin alone in patients with nonalcoholic fatty liver disease |
| Q36222629 | Combined influence of nonalcoholic fatty liver and body size phenotypes on diabetes risk |
| Q30248535 | Comparative efficacy of interventions on nonalcoholic fatty liver disease (NAFLD): A PRISMA-compliant systematic review and network meta-analysis |
| Q64112088 | Comparison of the prevalence, severity, and risk factors for hepatic steatosis in HIV-infected and uninfected people |
| Q64269900 | Comprehensive bioinformatics analysis of critical lncRNAs, mRNAs and miRNAs in non‑alcoholic fatty liver disease |
| Q48291953 | Correlation between obesity and fat-infiltrated axillary lymph nodes visualized on mammography. |
| Q36261892 | Curcumin prevents the non-alcoholic fatty hepatitis via mitochondria protection and apoptosis reduction |
| Q88289175 | Current State of Knowledge on Implications of Gut Microbiome for Surgical Conditions |
| Q58700636 | Current status of imaging in nonalcoholic fatty liver disease |
| Q57478272 | Danger-Associated Molecular Patterns (DAMPs): Molecular Triggers for Sterile Inflammation in the Liver |
| Q99237915 | Deficiency of CD147 Attenuated Non-alcoholic Steatohepatitis Progression in an NLRP3-Dependent Manner |
| Q50978081 | Deletion of HNF1α in hepatocytes results in fatty liver-related hepatocellular carcinoma in mice. |
| Q40285171 | Deletion of Macrophage Mineralocorticoid Receptor Protects Hepatic Steatosis and Insulin Resistance Through ERα/HGF/Met Pathway |
| Q47743188 | Deletion of endoplasmic reticulum stress-responsive co-chaperone p58IPK protects mice from diet-induced steatohepatitis. |
| Q91601376 | Descriptive Usability Study of CirrODS: Clinical Decision and Workflow Support Tool for Management of Patients With Cirrhosis |
| Q94463825 | Determining the role for uric acid in non-alcoholic steatohepatitis development and the utility of urate metabolites in diagnosis: An opinion review |
| Q92147548 | Development and validation of a simple risk model to predict major cancers for patients with nonalcoholic fatty liver disease |
| Q36411014 | Development of a classification model for non-alcoholic steatohepatitis (NASH) using confocal Raman micro-spectroscopy. |
| Q50420689 | Developmental origins of non-alcoholic fatty liver disease as a risk factor for exaggerated metabolic and cardiovascular-renal disease. |
| Q89472806 | Diagnostic Accuracy of Shear Wave Elastography as a Non-invasive Biomarker of High-Risk Non-alcoholic Steatohepatitis in Patients with Non-alcoholic Fatty Liver Disease |
| Q58713138 | Diagnostic accuracy of point shear wave elastography and transient elastography for staging hepatic fibrosis in patients with non-alcoholic fatty liver disease: a meta-analysis |
| Q64230514 | Diagnostic and Treatment Implications of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis |
| Q88794981 | Diagnostic performance of magnetic resonance technology in detecting steatosis or fibrosis in patients with nonalcoholic fatty liver disease: A meta-analysis |
| Q90452363 | Diet Quality Association with Nonalcoholic Fatty Liver Disease by Cirrhosis Status: The Multiethnic Cohort |
| Q59807439 | Dietary DHA/EPA Ratio Changes Fatty Acid Composition and Attenuates Diet-Induced Accumulation of Lipid in the Liver of ApoE Mice |
| Q49810183 | Dietary fat stimulates development of NAFLD more potently than dietary fructose in Sprague-Dawley rats |
| Q39304864 | Dietary sodium and potassium intake in relation to non-alcoholic fatty liver disease |
| Q47692256 | Dimethylguanidino valeric acid is a marker of liver fat and predicts diabetes. |
| Q36047930 | Discrimination of Nonalcoholic Steatohepatitis Using Transient Elastography in Patients with Nonalcoholic Fatty Liver Disease |
| Q90094737 | Dissociating nonalcoholic steatohepatitis from hepatocellular carcinoma in obesity |
| Q92436257 | Does Turmeric/curcumin Supplementation Change Anthropometric Indices in Patients with Non-alcoholic Fatty Liver Disease? A Systematic Review and Meta-analysis of Randomized Controlled Trials |
| Q64099624 | Dose-response association between physical activity and non-alcoholic fatty liver disease: a case-control study in a Chinese population |
| Q61808214 | Drug-Induced Liver Injury Caused by Kratom Use as an Alternative Pain Treatment Amid an Ongoing Opioid Epidemic |
| Q93135880 | Dual-release hydrocortisone improves hepatic steatosis in patients with secondary adrenal insufficiency: a real-life study |
| Q58619660 | Dynamic PET of human liver inflammation: impact of kinetic modeling with optimization-derived dual-blood input function |
| Q33779040 | Early Intervention With Live Donor Liver Transplantation Reduces Resource Utilization in NASH: The Toronto Experience |
| Q38968164 | Early redox imbalance is associated with liver dysfunction at weaning in overfed rats |
| Q30252463 | Editorial: Age and Non-Invasive Markers of Fibrosis in Patients With Nonalcoholic Fatty Liver Disease: Time to Adjust the Clock? |
| Q87781321 | Editorial: Magnetic Resonance Elastography and Non-Alcoholic Fatty Liver Disease: Time for an Upgrade? |
| Q92509579 | Effect of Age on Diabetogenicity of Alloxan in Ossabaw Miniature Swine |
| Q50526705 | Effect of PNPLA3 I148M polymorphism on histologically proven non-alcoholic fatty liver disease in liver transplant recipients. |
| Q92088291 | Effect of garlic powder supplementation on hepatic steatosis, liver enzymes, and lipid profile in patients with non-alcoholic fatty liver disease: A double-blind randomized controlled clinical trial |
| Q99548937 | Effects of Omega-3 Polyunsaturated Fatty Acid Supplementation on Non-Alcoholic Fatty Liver: A Systematic Review and Meta-Analysis |
| Q58549943 | Effects of Pioglitazone on Nonalcoholic Fatty Liver Disease in the Absence of Constitutive Androstane Receptor Expression |
| Q93264367 | Effects of canagliflozin on body composition and hepatic fat content in type 2 diabetes patients with non-alcoholic fatty liver disease |
| Q48220163 | Effects of combined low-dose spironolactone plus vitamin E vs vitamin E monotherapy on insulin resistance, non-invasive indices of steatosis and fibrosis, and adipokine levels in non-alcoholic fatty liver disease: a randomized controlled trial |
| Q89414485 | Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study |
| Q92005722 | Effects of glucagon-like peptide 1 receptor agonists on comorbidities in older patients with diabetes mellitus |
| Q100429913 | Effects of sodium-glucose co-transporter 2 inhibitors on liver parameters and steatosis: A meta-analysis of randomized clinical trials |
| Q57459118 | Efficacy and Clinical Value of Liraglutide for Treatment of Diabetes Mellitus Complicated by Non-Alcoholic Fatty Liver Disease |
| Q47191893 | Efficacy of nanocurcumin supplementation on insulin resistance, lipids, inflammatory factors and nesfatin among obese patients with non-alcoholic fatty liver disease (NAFLD): a trial protocol |
| Q98210261 | Efficacy of vitamin D supplement in children with nonalcoholic fatty liver disease: A protocol for systematic review and meta-analysis |
| Q42377919 | Elevated hepatic DPP4 activity promotes insulin resistance and non-alcoholic fatty liver disease |
| Q38827586 | Emerging and future therapies for nonalcoholic steatohepatitis in adults |
| Q60303868 | Empagliflozin promises to bridge the gap between non-alcoholic fatty liver disease, type 2 diabetes, and cardiovascular disease |
| Q30234414 | Endocrine-disrupting chemicals and fatty liver disease. |
| Q91654810 | Epidemiology of non-alcoholic and alcoholic fatty liver diseases |
| Q92814833 | Essential Amino Acid Supplement Lowers Intrahepatic Lipid despite Excess Alcohol Consumption |
| Q26745566 | Evolving Insights on Metabolism, Autophagy, and Epigenetics in Liver Myofibroblasts |
| Q33807881 | Exosomes derived from palmitic acid-treated hepatocytes induce fibrotic activation of hepatic stellate cells |
| Q91854644 | Experimental Validation of Longitudinal Speed of Sound Estimates in the Diagnosis of Hepatic Steatosis (Part II) |
| Q36921610 | Extrahepatic Manifestations of Nonalcoholic Fatty Liver Disease |
| Q48225055 | Fatty allograft and cardiovascular outcomes after liver transplantation |
| Q64230305 | Fatty liver disease and the risk of erosive oesophagitis in the Korean population: a cross-sectional study |
| Q33574490 | Fatty liver disease determines the progression of coronary artery calcification in a metabolically healthy obese population |
| Q64986242 | Fatty liver disease in persons with HIV infection. |
| Q90579602 | Fatty liver disrupts glycerol metabolism in gluconeogenic and lipogenic pathways in humans |
| Q39179707 | Fetuin-A and Risk of Diabetes Independent of Liver Fat Content: The Multi-Ethnic Study of Atherosclerosis |
| Q53625645 | Flaxseed supplementation in non-alcoholic fatty liver disease: a pilot randomized, open labeled, controlled study. |
| Q46803886 | Free-breathing liver fat quantification using a multiecho 3D stack-of-radial technique |
| Q88574567 | Free-breathing quantification of hepatic fat in healthy children and children with nonalcoholic fatty liver disease using a multi-echo 3-D stack-of-radial MRI technique |
| Q90615264 | Gaining New Biological and Therapeutic Applications into the Liver with 3D In Vitro Liver Models |
| Q40338492 | Gastrointestinal Complications of Obesity |
| Q52644448 | Genetic and Epigenetic Regulation in Nonalcoholic Fatty Liver Disease (NAFLD). |
| Q38798845 | Genetic and hormonal control of hepatic steatosis in female and male mice |
| Q30235398 | Genetic predisposition in nonalcoholic fatty liver disease |
| Q92938440 | Genetic studies of abdominal MRI data identify genes regulating hepcidin as major determinants of liver iron concentration |
| Q47416884 | Genistein Ameliorates Fat Accumulation Through AMPK Activation in Fatty Acid-Induced BRL Cells |
| Q38404438 | Glu-Phe from onion (Allium Cepa L.) attenuates lipogenesis in hepatocytes |
| Q94525937 | Glucocorticoid-Induced Fatty Liver Disease |
| Q90708951 | Glutamine Breakdown as a Potential Metabolic Biomarker for Nonalcoholic Steatohepatitis |
| Q64100967 | Green cardamom supplementation improves serum irisin, glucose indices, and lipid profiles in overweight or obese non-alcoholic fatty liver disease patients: a double-blind randomized placebo-controlled clinical trial |
| Q38806840 | Gut Microbiome-Based Metagenomic Signature for Non-invasive Detection of Advanced Fibrosis in Human Nonalcoholic Fatty Liver Disease |
| Q94593791 | Gypenosides regulate farnesoid X receptor-mediated bile acid and lipid metabolism in a mouse model of non-alcoholic steatohepatitis |
| Q91956667 | Have incidence rates of liver cancer peaked in the United States? |
| Q88724024 | Healthcare Cost and Utilization in Nonalcoholic Fatty Liver Disease: Real-World Data From a Large U.S. Claims Database |
| Q36621532 | Helicobacter pylori infection is not associated with nonalcoholic fatty liver disease |
| Q52808488 | Hepatic Lipophagy: New Insights into Autophagic Catabolism of Lipid Droplets in the Liver. |
| Q92289451 | Hepatic Mitochondrial Oxidative Metabolism and Lipogenesis Synergistically Adapt to Mediate Healthy Embryonic-to-Neonatal Transition in Chicken |
| Q60947742 | Hepatic Steatosis Index in Acromegaly: Correlation with Insulin Resistance Regardless of the Disease Control |
| Q33687175 | Hepatic estrogen receptor α is critical for regulation of gluconeogenesis and lipid metabolism in males |
| Q47589822 | Hepatic neuregulin 4 signaling defines an endocrine checkpoint for steatosis-to-NASH progression |
| Q41506217 | Hepatocellular Carcinoma in the Setting of Non-cirrhotic Nonalcoholic Fatty Liver Disease and the Metabolic Syndrome: US Experience |
| Q28066100 | Hepatocellular carcinoma in patients with non-alcoholic fatty liver disease |
| Q28069290 | Hepatocellular carcinoma: a review |
| Q50095660 | Hepatocyte DUSP14 maintains metabolic homeostasis and suppresses inflammation in the liver |
| Q61099995 | Hepatocyte Lethal and Nonlethal Lipotoxic Injury |
| Q93335540 | Hepatocyte Notch activation induces liver fibrosis in nonalcoholic steatohepatitis |
| Q46109785 | Hepatocyte TAZ/WWTR1 Promotes Inflammation and Fibrosis in Nonalcoholic Steatohepatitis |
| Q60947050 | Hepatocyte-Derived Lipotoxic Extracellular Vesicle Sphingosine 1-Phosphate Induces Macrophage Chemotaxis |
| Q30701525 | Hepatocytes release ceramide-enriched pro-inflammatory extracellular vesicles in an IRE1α-dependent manner |
| Q93144314 | Hepatoprotective Role of Eclipta alba against High Fatty Diet Treated Experimental Models - A Histopathological Study |
| Q48363625 | Hepatoprotective effect of parthenolide in rat model of nonalcoholic fatty liver disease |
| Q36502066 | Hepcidin in non-alcoholic fatty liver disease regulated by the TLR4/NF-κB signaling pathway |
| Q52724124 | High frequency of the PNPLA3 rs738409 [G] single-nucleotide polymorphism in Hmong individuals as a potential basis for a predisposition to chronic liver disease. |
| Q86432405 | High prevalence of hepatic fibrosis in the setting of coexisting diabetes and hepatic steatosis: A case for selective screening in the general population? |
| Q50199746 | Hippo-mediated suppression of IRS2/AKT signaling prevents hepatic steatosis and liver cancer |
| Q57144815 | Histological improvement of non-alcoholic steatohepatitis with a prebiotic: a pilot clinical trial |
| Q98293262 | Hospitalization costs and risk of mortality in adults with nonalcoholic steatohepatitis: Analysis of a French national hospital database |
| Q53688960 | Hyperandrogenism and insulin resistance contribute to hepatic steatosis and inflammation in female rat liver. |
| Q98159064 | Identification of hub genes involved in the occurrence and development of hepatocellular carcinoma via bioinformatics analysis |
| Q90447292 | Identification of key pathways and genes in nonalcoholic fatty liver disease using bioinformatics analysis |
| Q88738844 | Identifying Nonalcoholic Fatty Liver Disease Advanced Fibrosis in the Veterans Health Administration |
| Q61808847 | Identifying and Treating Nonalcoholic Fatty Liver Disease |
| Q89768159 | Impact of Demographic Factors and Systemic Disease on Urinary Stone Risk Parameters Amongst Stone Formers |
| Q90616755 | Impact of Skeletal Muscle Mass on Metabolic Health |
| Q43951595 | Impact of intracellular glyceraldehyde-derived advanced glycation end-products on human hepatocyte cell death. |
| Q88492904 | Impact of miR-140 Deficiency on Non-Alcoholic Fatty Liver Disease |
| Q50455460 | Impaired learning and memory in rats induced by a high-fat diet: Involvement with the imbalance of nesfatin-1 abundance and copine 6 expression. |
| Q51731744 | Improved Diet Quality Associates With Reduction in Liver Fat-Particularly in Individuals With High Genetic Risk Scores for Nonalcoholic Fatty Liver Disease. |
| Q89506377 | Inadequate Physical Activity and Sedentary Behavior Are Independent Predictors of Nonalcoholic Fatty Liver Disease |
| Q57492312 | Inadequate identification of fatty liver disease, obesity, and metabolic syndrome by family physicians |
| Q89492623 | Inborn errors of metabolism in the differential diagnosis of fatty liver disease |
| Q95384771 | Increased hepatocellular carcinoma recurrence in women compared to men with high alpha fetoprotein at liver transplant |
| Q30238749 | Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis |
| Q58598215 | Increased risk of osteoporosis in patients with nonalcoholic fatty liver disease: A population-based retrospective cohort study |
| Q51763086 | Increasing co-morbidities in chronic hepatitis B patients: experience in primary care and referral practices during 2000-2015. |
| Q92340368 | Increasing metabolic co-morbidities are associated with higher risk of advanced fibrosis in nonalcoholic steatohepatitis |
| Q92501696 | Independent markers of nonalcoholic fatty liver disease in a gentrifying population-based Chinese cohort |
| Q54942348 | Inflammatory Biomarkers and Risk of Atherosclerotic Cardiovascular Disease. |
| Q35842213 | Influence of Fatty Liver on the Severity and Clinical Outcome in Acute Pancreatitis |
| Q39049164 | Inhibition of sphingosine 1-phosphate signaling ameliorates murine nonalcoholic steatohepatitis |
| Q92089595 | Insights into the Epidemiology, Pathogenesis, and Therapeutics of Nonalcoholic Fatty Liver Diseases |
| Q46419763 | Interleukin-33 drives hepatic fibrosis through activation of hepatic stellate cells |
| Q39085029 | Interval increase in the prevalence of symptomatic cholelithiasis-associated non-alcoholic fatty liver disease over a ten-year period in an Asian population. |
| Q64101021 | Investigating the deregulation of metabolic tasks via Minimum Network Enrichment Analysis (MiNEA) as applied to nonalcoholic fatty liver disease using mouse and human omics data |
| Q38790566 | Involvement of senescence marker protein-30 in glucose metabolism disorder and non-alcoholic fatty liver disease |
| Q35957448 | Ipragliflozin Improves Hepatic Steatosis in Obese Mice and Liver Dysfunction in Type 2 Diabetic Patients Irrespective of Body Weight Reduction |
| Q48263840 | Ipragliflozin and sodium glucose transporter 2 inhibitors to reduce liver fat: will the prize we sought be won? |
| Q38725581 | Keratins: Biomarkers and modulators of apoptotic and necrotic cell death in the liver. |
| Q55071759 | Key Inflammatory Processes in Human NASH Are Reflected in Ldlr-/-.Leiden Mice: A Translational Gene Profiling Study. |
| Q42172913 | Lack of NLRP3-inflammasome leads to gut-liver axis derangement, gut dysbiosis and a worsened phenotype in a mouse model of NAFLD. |
| Q94400448 | Lifestyle modifications for non‐alcohol related fatty liver disease: a network meta‐analysis |
| Q40979699 | Linarin Enriched Extract Attenuates Liver Injury and Inflammation Induced by High-Fat High-Cholesterol Diet in Rats |
| Q92798647 | Lipometabolism and Glycometabolism in Liver Diseases |
| Q38799232 | Lipotoxic lethal and sublethal stress signaling in hepatocytes: relevance to NASH pathogenesis. |
| Q36775647 | Lipotoxicity in steatohepatitis occurs despite an increase in tricarboxylic acid cycle activity |
| Q91906211 | Liraglutide ameliorates nonalcoholic fatty liver disease in diabetic mice via the IRS2/PI3K/Akt signaling pathway |
| Q91078828 | Liver Fat and Cardiometabolic Risk Factors Among School-Age Children |
| Q40108169 | Liver Transplantation for Nonalcoholic Steatohepatitis in the US: Temporal Trends and Outcomes |
| Q64063908 | Liver-related mortality in the United States: hepatitis C declines, non-alcoholic fatty liver and alcohol rise |
| Q37348806 | LncRNA SRA promotes hepatic steatosis through repressing the expression of adipose triglyceride lipase (ATGL). |
| Q41688159 | Lone Hepatocellular Carcinoma: An Isolated Chest Wall Malignancy |
| Q61135312 | Long noncoding RNA licensing of obesity-linked hepatic lipogenesis and NAFLD pathogenesis |
| Q37405570 | Long-term lifestyle interventions in middle-aged and elderly men with nonalcoholic fatty liver disease: a randomized controlled trial |
| Q40181436 | Low Birthweight Increases the Likelihood of Severe Steatosis in Pediatric Non-Alcoholic Fatty Liver Disease |
| Q38867829 | MRI and MRE for non-invasive quantitative assessment of hepatic steatosis and fibrosis in NAFLD and NASH: Clinical trials to clinical practice |
| Q90648104 | Magnesium isoglycyrrhizinate ameliorates high fructose-induced liver fibrosis in rat by increasing miR-375-3p to suppress JAK2/STAT3 pathway and TGF-β1/Smad signaling |
| Q40444861 | Magnetic Resonance Elastography vs Transient Elastography in Detection of Fibrosis and Noninvasive Measurement of Steatosis in Patients With Biopsy-Proven Nonalcoholic Fatty Liver Disease |
| Q53704720 | Managing the Burden of Non-NASH NAFLD. |
| Q50053108 | Maraviroc improves hepatic triglyceride content but not inflammation in a murine nonalcoholic fatty liver disease model induced by a chronic exposure to high-fat diet. |
| Q64093846 | Matrine Protects Against MCD-Induced Development of NASH via Upregulating HSP72 and Downregulating mTOR in a Manner Distinctive From Metformin |
| Q59330033 | Matrine attenuates endoplasmic reticulum stress and mitochondrion dysfunction in nonalcoholic fatty liver disease by regulating SERCA pathway |
| Q88691982 | Mechanisms by Which Dietary Fatty Acids Regulate Mitochondrial Structure-Function in Health and Disease |
| Q40380042 | Mechanisms of the prevention and inhibition of the progression and development of non-alcoholic steatohepatitis by genetic and pharmacological decoy receptor 3 supplementation |
| Q44339679 | Mediterranean Diet and Multi-Ingredient-Based Interventions for the Management of Non-Alcoholic Fatty Liver Disease. |
| Q37431846 | Melatonin improves non-alcoholic fatty liver disease via MAPK-JNK/P38 signaling in high-fat-diet-induced obese mice |
| Q51241412 | Mendelian randomization estimates of alanine aminotransferase with cardiovascular disease: Guangzhou Biobank Cohort study. |
| Q51289305 | Metabolic Impact of Nonalcoholic Steatohepatitis in Obese Patients With Type 2 Diabetes. |
| Q49394966 | Metabolic and hepatic effects of liraglutide, obeticholic acid and elafibranor in diet-induced obese mouse models of biopsy-confirmed nonalcoholic steatohepatitis |
| Q93066805 | Metabolic factors affecting hepatocellular carcinoma in steatohepatitis |
| Q61454431 | Metabolic profiling of adolescent non-alcoholic fatty liver disease |
| Q64107847 | Metabolomics Characterizes the Effects and Mechanisms of Quercetin in Nonalcoholic Fatty Liver Disease Development |
| Q47142430 | MicroRNA deregulation in nonalcoholic steatohepatitis-associated liver carcinogenesis |
| Q64119480 | MicroRNA-29a Disrupts DNMT3b to Ameliorate Diet-Induced Non-Alcoholic Steatohepatitis in Mice |
| Q47947610 | MicroRNAs as biomarkers for clinical studies |
| Q26774294 | MicroRNAs in Nonalcoholic Fatty Liver Disease |
| Q92861568 | Microarray Expression Profiling and Raman Spectroscopy Reveal Anti-Fatty Liver Action of Berberine in a Diet-Induced Larval Zebrafish Model |
| Q39363389 | Microbiome and NAFLD: potential influence of aerobic fitness and lifestyle modification |
| Q92338109 | Minimally Invasive Sleeve Gastrectomy as a Surgical Treatment for Nonalcoholic Fatty Liver Disease in Liver Transplant Recipients |
| Q37652049 | Mitochondrial ATP transporter depletion protects mice against liver steatosis and insulin resistance |
| Q47655604 | Mitochondrial dysfunction and damage associated molecular patterns (DAMPs) in chronic inflammatory diseases |
| Q40536891 | Mitochondrial genome architecture in non-alcoholic fatty liver disease |
| Q38627907 | Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease |
| Q60916300 | Modulation of Gut Microbiota by L. Berry Polyphenols in a Mouse Model of Fatty Liver Induced by High Fat Diet |
| Q58117144 | Modulation of gut microbiome in nonalcoholic fatty liver disease: pro-, pre-, syn-, and antibiotics |
| Q38711019 | Morin, a novel liver X receptor α/β dual antagonist, has potent therapeutic efficacy for nonalcoholic fatty liver diseases. |
| Q50202622 | Morphofunctional Changes After Sleeve Gastrectomy and Very Low Calorie Diet in an Animal Model of Non-Alcoholic Fatty Liver Disease |
| Q54212012 | Mouse models for investigating the underlying mechanisms of nonalcoholic steatohepatitis-derived hepatocellular carcinoma. |
| Q54717572 | Multiparametric magnetic resonance imaging in patients with chronic liver disease: are we there yet? |
| Q100994711 | NASH: Connecting the dots with patients in mind |
| Q91918984 | NGM282 Improves Liver Fibrosis and Histology in 12 Weeks in Patients With Nonalcoholic Steatohepatitis |
| Q51742682 | NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. |
| Q91902571 | Natural course of fatty liver in 36,195 South Korean adults |
| Q55482826 | Neonatal overfeeding induced glucocorticoid overexposure accelerates hepatic lipogenesis in male rats. |
| Q52725811 | Neutrophil-Hepatic Stellate Cell Interactions Promote Fibrosis in Experimental Steatohepatitis. |
| Q41608549 | New botanical drug, HL tablet, reduces hepatic fat as measured by magnetic resonance spectroscopy in patients with nonalcoholic fatty liver disease: A placebo-controlled, randomized, phase II trial |
| Q39030264 | Non-Alcoholic Fatty Liver Disease: Cause or Effect of Metabolic Syndrome |
| Q47156332 | Non-Alcoholic Fatty Liver Disease: The Emerging Burden in Cardiometabolic and Renal Diseases |
| Q58731134 | Non-HDL-cholesterol to HDL-cholesterol ratio is a better predictor of new-onset non-alcoholic fatty liver disease than non-HDL-cholesterol: a cohort study |
| Q60928427 | Non-HDL-cholesterol to HDL-cholesterol ratio is an independent risk factor for liver function tests abnormalities in geriatric population |
| Q36560817 | Non-alcoholic Fatty Liver Disease (NAFLD) is associated with impairment of Health Related Quality of Life (HRQOL). |
| Q30234443 | Non-alcoholic Fatty Liver Disease in South Asians: A Review of the Literature |
| Q47100244 | Non-alcoholic Fatty Liver Disease: A Clinical Update |
| Q55512053 | Non-alcoholic Fatty Liver Disease: A Review of Anti-diabetic Pharmacologic Therapies. |
| Q37215934 | Non-alcoholic fatty liver and the gut microbiota |
| Q56003593 | Non-alcoholic fatty liver disease |
| Q36859981 | Non-alcoholic fatty liver disease is not associated with a lower health perception |
| Q91264430 | Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies |
| Q53833366 | Non-alcoholic steatofibrosis (NASF) can independently predict mortality in patients with non-alcoholic fatty liver disease (NAFLD). |
| Q49790075 | Non-alcoholic steatohepatitis pathogenesis: sublethal hepatocyte injury as a driver of liver inflammation |
| Q50071030 | Non-invasive diagnosis of non-alcoholic fatty liver disease (NAFLD) using ultrasound image echogenicity |
| Q94465389 | Nonalcoholic Fatty Liver Disease Is Associated With Low Skeletal Muscle Mass in Overweight/Obese Youths |
| Q47134584 | Nonalcoholic Fatty Liver Disease Is Not Associated with Thyroid Hormone Levels and Hypothyroidism: A Systematic Review and Meta-Analysis |
| Q64113047 | Nonalcoholic Fatty Liver Disease and Diabetes: Part II: Treatment |
| Q63681503 | Nonalcoholic Fatty Liver Disease in The Rotterdam Study: About Muscle Mass, Sarcopenia, Fat Mass, and Fat Distribution |
| Q55512582 | Nonalcoholic Fatty Liver Disease in University Rugby Football Players. |
| Q99405789 | Nonalcoholic Fatty Liver Disease: Making the Diagnosis |
| Q89216668 | Nonalcoholic fatty liver disease |
| Q55122484 | Nonalcoholic fatty liver disease and the ongoing role of liver biopsy evaluation. |
| Q26749290 | Nonalcoholic fatty liver disease as a multi-systemic disease |
| Q91841807 | Nonalcoholic fatty liver disease experiences accumulation of hepatic liquid crystal associated with increasing lipophagy |
| Q55427479 | Nonalcoholic fatty liver disease with elevated alanine aminotransferase levels is negatively associated with bone mineral density: Cross-sectional study in U.S. adults. |
| Q89464483 | Nonalcoholic fatty liver disease- evidence for a thrombophilic state? |
| Q55399317 | Nonalcoholic fatty liver disease-related cirrhosis is commonly unrecognized and associated with hepatocellular carcinoma. |
| Q52562619 | Nonalcoholic fatty liver disease: epidemiology, pathogenesis and therapeutic implications. |
| Q36673799 | Nonalcoholic fatty liver: optimizing pretransplant selection and posttransplant care to maximize survival |
| Q92070614 | Nonalcoholic steatohepatitis Fitness Intervention in Thrombosis (NASHFit): Study protocol for a randomized controlled trial of a supervised aerobic exercise program to reduce elevated clotting risk in patients with NASH |
| Q45042166 | Nonalcoholic steatohepatitis is associated with a state of betaine-insufficiency |
| Q30234736 | Nonalcoholic steatohepatitis-related hepatocellular carcinoma: is there a role for the androgen receptor pathway? |
| Q26796448 | Nonalcoholic steatohepatitis: emerging targeted therapies to optimize treatment options |
| Q38708566 | Noninvasive Assessment of Advanced Fibrosis Based on Hepatic Volume in Patients with Nonalcoholic Fatty Liver Disease |
| Q94521157 | Novel Combinatorial Regimen of Garcinol and Curcuminoids for Non-alcoholic Steatohepatitis (NASH) in Mice |
| Q37097358 | Novel molecular triggers underlie valproate-induced liver injury and its alleviation by the omega-3 fatty acid DHA: role of inflammation and apoptosis |
| Q40086170 | Nutrition, inflammation and liver-spleen axis. |
| Q39180598 | Nutritional Approaches to Achieve Weight Loss in Nonalcoholic Fatty Liver Disease |
| Q94400535 | Nutritional supplementation for non‐alcohol‐related fatty liver disease: a network meta‐analysis |
| Q38791485 | Obesity is an independent risk factor for non-alcoholic fatty liver disease: evidence from a meta-analysis of 21 cohort studies |
| Q45903563 | Occult liver disease burden: Analysis from a large general practitioners' database. |
| Q60932796 | One in five hepatocellular carcinoma patients in the United States are Hispanic while less than 40% were eligible for liver transplantation |
| Q33844302 | Oral arginine supplementation protects female mice from the onset of non-alcoholic steatohepatitis |
| Q64083341 | Organoids of liver diseases: From bench to bedside |
| Q37532228 | Outcome of phlebotomy for treating nonalcoholic fatty liver disease: A systematic review and meta-analysis |
| Q33817373 | Over-expressing the soluble gp130-Fc does not ameliorate methionine and choline deficient diet-induced non alcoholic steatohepatitis in mice. |
| Q57793170 | Overproduction of Tenascin-C Driven by Lipid Accumulation in Liver Aggravates Hepatic Ischemia and Reperfusion Injury in Steatotic Mice |
| Q38912628 | Oxidized LDL at the crossroads of immunity in non-alcoholic steatohepatitis |
| Q64078675 | PCAT-1: A Novel Oncogenic Long Non-Coding RNA in Human Cancers |
| Q39029023 | PPARs and nonalcoholic fatty liver disease |
| Q38674742 | PPARs: regulators of metabolism and as therapeutic targets in cardiovascular disease. Part I: PPAR-α. |
| Q64082428 | Pediatric Fatty Liver Disease |
| Q90566894 | Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial |
| Q92491583 | Perceived stress and non-alcoholic fatty liver disease in apparently healthy men and women |
| Q38867031 | Pharmacological interventions for non-alcohol related fatty liver disease (NAFLD): an attempted network meta-analysis. |
| Q37504529 | Phospholipase D1 deficiency in mice causes nonalcoholic fatty liver disease via an autophagy defect |
| Q90273159 | Physical activity intervention for non-diabetic patients with non-alcoholic fatty liver disease: a meta-analysis of randomized controlled trials |
| Q88316703 | Pioglitazone improves hepatic mitochondrial function in a mouse model of nonalcoholic steatohepatitis |
| Q91638410 | Polysaccharide extracted from WuGuChong reduces high-fat diet-induced obesity in mice by regulating the composition of intestinal microbiota |
| Q33851122 | Prevalence and predictors of irritable bowel syndrome in patients with morbid obesity: a cross-sectional study |
| Q36649345 | Prevalence and predictors of non-alcoholic fatty liver disease as defined by the fatty liver index in a type 2 diabetes population |
| Q33832177 | Prevalence of Non Alcoholic Fatty Liver Disease and its Association with Diabetic Nephropathy in Patients with Type 2 Diabetes Mellitus |
| Q39343214 | Prevalence of abnormal serum liver enzymes in patients with type 2 diabetes mellitus: a cross-sectional study from China |
| Q40701165 | Prevalence of chronic liver disease and cirrhosis by underlying cause in understudied ethnic groups: The multiethnic cohort |
| Q50005567 | Proceedings of the 2017 ASPEN Research Workshop-Gastric Bypass: Role of the Gut. |
| Q55114119 | Prolonged cenicriviroc therapy reduces hepatic fibrosis despite steatohepatitis in a diet-induced mouse model of nonalcoholic steatohepatitis. |
| Q92147100 | Proteomic screening of plasma identifies potential noninvasive biomarkers associated with significant/advanced fibrosis in patients with nonalcoholic fatty liver disease |
| Q39967628 | Psoriasis and the liver: problems, causes and course |
| Q90599568 | Pyroptosis in Liver Disease: New Insights into Disease Mechanisms |
| Q90279848 | Quantification of Liver Fat Content With Unenhanced MDCT: Phantom and Clinical Correlation With MRI Proton Density Fat Fraction |
| Q41682600 | Quantitative imaging of fibrotic and morphological changes in liver of non-alcoholic steatohepatitis (NASH) model mice by second harmonic generation (SHG) and auto-fluorescence (AF) imaging using two-photon excitation microscopy (TPEM). |
| Q47880294 | Racial and Ethnic Disparities in Nonalcoholic Fatty Liver Disease Prevalence, Severity, and Outcomes in the United States: A Systematic Review and Meta-analysis. |
| Q38728953 | Rationally combining anti-VEGF therapy with checkpoint inhibitors in hepatocellular carcinoma |
| Q56378244 | Reader agreement and accuracy of ultrasound features for hepatic steatosis |
| Q38665591 | Recent advances in understanding the role of adipocytokines during non-alcoholic fatty liver disease pathogenesis and their link with hepatokines |
| Q89977091 | Reclassifying Hepatic Cell Death during Liver Damage: Ferroptosis-A Novel Form of Non-Apoptotic Cell Death? |
| Q47096273 | Relationship between Hypothyroidism and Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-analysis |
| Q100635338 | Relative fat mass at baseline and its early change may be a predictor of incident nonalcoholic fatty liver disease |
| Q92579882 | Relevance between Helicobacter pylori Infection and Non-Alcoholic Fatty Liver Disease in Birjand, Iran |
| Q41217227 | Resting and Exercise Energy Metabolism After Liver Transplantation for Nonalcoholic Steatohepatitis |
| Q37392542 | Risk factor compositions of nonalcoholic fatty liver disease change with body mass index in males and females |
| Q45325816 | Risk factors for biopsy-proven advanced non-alcoholic fatty liver disease in the Veterans Health Administration. |
| Q49334378 | Risk factors for hepatic steatosis in adults with cystic fibrosis: Similarities to non-alcoholic fatty liver disease |
| Q89724932 | Risk factors for hepatocellular carcinoma (HCC) in the northeast of the United States: results of a case-control study |
| Q37685731 | Risk factors for hepatocellular carcinoma in cirrhosis due to nonalcoholic fatty liver disease: A multicenter, case-control study. |
| Q92604714 | Role and effective therapeutic target of gut microbiota in NAFLD/NASH |
| Q90378269 | Role of ATP-binding cassette transporter A1 in suppressing lipid accumulation by glucagon-like peptide-1 agonist in hepatocytes |
| Q89497203 | Role of Hepatokines in Non-alcoholic Fatty Liver Disease |
| Q61809313 | Role of Nutrition in the Pathogenesis and Prevention of Non-alcoholic Fatty Liver Disease: Recent Updates |
| Q92445643 | Role of Overweight and Obesity in Gastrointestinal Disease |
| Q58740380 | Role of two-dimensional shear wave elastography in chronic liver diseases: A narrative review |
| Q64941384 | Ron Receptor Signaling Ameliorates Hepatic Fibrosis in a Diet-Induced Nonalcoholic Steatohepatitis Mouse Model. |
| Q91906202 | SGLT-2 inhibitors as promising therapeutics for non-alcoholic fatty liver disease: pathophysiology, clinical outcomes, and future directions |
| Q37419220 | SUMO-specific protease 3 is a key regulator for hepatic lipid metabolism in non-alcoholic fatty liver disease. |
| Q37583677 | Salsalate (Salicylate) Uncouples Mitochondria, Improves Glucose Homeostasis, and Reduces Liver Lipids Independent of AMPK-β1 |
| Q90067935 | Sarcopenia Is Independently Associated with the Degree of Liver Fibrosis in Patients with Type 2 Diabetes Mellitus |
| Q91788949 | Sarcopenia Is Significantly Associated with Presence and Severity of Nonalcoholic Fatty Liver Disease |
| Q64092690 | Sarcopenia and nonalcoholic fatty liver disease: a causal relationship |
| Q40241316 | Sarcopenia is associated with significant liver fibrosis independently of obesity and insulin resistance in nonalcoholic fatty liver disease: Nationwide surveys (KNHANES 2008-2011). |
| Q89496310 | Saturated fatty acid combined with lipopolysaccharide stimulates a strong inflammatory response in hepatocytes in vivo and in vitro |
| Q52384622 | Serine/threonine protein kinase 25 antisense oligonucleotide treatment reverses glucose intolerance, insulin resistance, and nonalcoholic fatty liver disease in mice. |
| Q92083075 | Serum Vitamin E Levels of Adults with Nonalcoholic Fatty Liver Disease: An Inverse Relationship with All-Cause Mortality in Non-Diabetic but Not in Pre-Diabetic or Diabetic Subjects |
| Q37339883 | Serum YKL-40 as a marker of liver fibrosis in patients with non-alcoholic fatty liver disease |
| Q90163452 | Serum bile acid patterns are associated with the presence of NAFLD in twins, and dose-dependent changes with increase in fibrosis stage in patients with biopsy-proven NAFLD |
| Q40257413 | Serum metabolomic profiling highlights pathways associated with liver fat content in a general population sample |
| Q40086139 | Severe Vitamin D Deficiency Is Not Associated with Liver Damage in Morbidly Obese Patients. |
| Q92049673 | Shaping of Innate Immune Response by Fatty Acid Metabolite Palmitate |
| Q58583666 | Sheng-Jiang Powder Ameliorates High Fat Diet Induced Nonalcoholic Fatty Liver Disease via Inhibiting Activation of Akt/mTOR/S6 Pathway in Rats |
| Q36902222 | Short-term aerobic exercise training improves gut peptide regulation in nonalcoholic fatty liver disease |
| Q38781182 | Significant Association Between Gallstone Disease and Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis |
| Q40039094 | Significant burden of nonalcoholic fatty liver disease with advanced fibrosis in the US: a cross-sectional analysis of 2011-2014 National Health and Nutrition Examination Survey. |
| Q33862990 | Silencing of FABP1 ameliorates hepatic steatosis, inflammation, and oxidative stress in mice with nonalcoholic fatty liver disease |
| Q92435715 | Silibinin ameliorates hepatic lipid accumulation and oxidative stress in mice with non-alcoholic steatohepatitis by regulating CFLAR-JNK pathway |
| Q38755145 | Silybin counteracts lipid excess and oxidative stress in cultured steatotic hepatic cells. |
| Q37572575 | Sodium butyrate attenuates high-fat diet-induced steatohepatitis in mice by improving gut microbiota and gastrointestinal barrier |
| Q59795593 | Sodium butyrate reduces high-fat diet-induced non-alcoholic steatohepatitis through upregulation of hepatic GLP-1R expression |
| Q52640242 | Spatial Systems Lipidomics Reveals Nonalcoholic Fatty Liver Disease Heterogeneity. |
| Q50086219 | Specialty Care Access Network-Extension of Community Healthcare Outcomes Model Program for Liver Disease Improves Specialty Care Access |
| Q35996623 | Status of hepatic DNA methylome predetermines and modulates the severity of non-alcoholic fatty liver injury in mice |
| Q89553910 | Structural modulation of gut microbiota during alleviation of non-alcoholic fatty liver disease with Gynostemma pentaphyllum in rats |
| Q47625275 | Survival after treatment with curative intent for hepatocellular carcinoma among patients with vs without non-alcoholic fatty liver disease. |
| Q90445584 | Sustained Improvements in Markers of Liver Disease Severity After Hepatitis C Treatment |
| Q39359052 | Systematic review and meta-analysis to determine the impact of iron depletion in dysmetabolic iron overload syndrome and non-alcoholic fatty liver disease |
| Q90170101 | TNFAIP8 regulates autophagy, cell steatosis, and promotes hepatocellular carcinoma cell proliferation |
| Q52745207 | TRAIL Deletion Prevents Liver, but Not Adipose Tissue, Inflammation during Murine Diet-Induced Obesity. |
| Q42343453 | Targeting FGF19/FGFR4 Pathway: A Novel Therapeutic Strategy for Hepatocellular Carcinoma. |
| Q64269581 | Tetramethylpyrazine reduces inflammation in the livers of mice fed a high fat diet |
| Q47177371 | Text messaging approach improves weight loss in patients with nonalcoholic fatty liver disease: A randomized study. |
| Q37673227 | The Effects of Myo-Inositol and B and D Vitamin Supplementation in the db/+ Mouse Model of Gestational Diabetes Mellitus |
| Q97871574 | The GLP-1R agonist liraglutide limits hepatic lipotoxicity and inflammatory response in mice fed a methionine-choline deficient diet |
| Q90259244 | The HAALT Non-invasive Scoring System for NAFLD in Obesity |
| Q50059733 | The Natural History of Nonalcoholic Fatty Liver Disease-An Evolving View |
| Q96229752 | The PPAR α/γ Agonist Saroglitazar Improves Insulin Resistance and Steatohepatitis in a Diet Induced Animal Model of Nonalcoholic Fatty Liver Disease |
| Q64119089 | The Paradoxical Protective Effect of Liver Steatosis on Severity and Functional Outcome of Ischemic Stroke |
| Q28078754 | The Potential Mechanisms of Berberine in the Treatment of Nonalcoholic Fatty Liver Disease |
| Q64114231 | The Relevance of Toxic AGEs (TAGE) Cytotoxicity to NASH Pathogenesis: A Mini-Review |
| Q41924860 | The Role of Diagnosis and Treatment of Underlying Liver Disease for the Prognosis of Primary Liver Cancer |
| Q98885228 | The Role of Exosomes in the Crosstalk between Adipocytes and Liver Cancer Cells |
| Q38752520 | The Role of Nuclear Receptors in the Pathophysiology, Natural Course, and Drug Treatment of NAFLD in Humans |
| Q39099711 | The Role of Tissue Macrophage-Mediated Inflammation on NAFLD Pathogenesis and Its Clinical Implications. |
| Q38683153 | The ZJU index is a powerful index for identifying NAFLD in the general Chinese population |
| Q61443874 | The association between adherence to the Mediterranean diet and hepatic steatosis: cross-sectional analysis of two independent studies, the UK Fenland Study and the Swiss CoLaus Study |
| Q92914480 | The association between nonalcoholic fatty liver disease and esophageal, stomach, or colorectal cancer: National population-based cohort study |
| Q89530725 | The association of serum total bile acid with non-alcoholic fatty liver disease in Chinese adults: a cross sectional study |
| Q60054202 | The associations among Helicobacter pylori infection, white blood cell count and nonalcoholic fatty liver disease in a large Chinese population |
| Q89623972 | The burden of non-alcoholic steatohepatitis (NASH) among patients from Europe: A real-world patient-reported outcomes study |
| Q58597634 | The correlation between controlled attenuation parameter and metabolic syndrome and its components in middle-aged and elderly nonalcoholic fatty liver disease patients |
| Q48326227 | The deubiquitinating enzyme cylindromatosis mitigates nonalcoholic steatohepatitis |
| Q91286660 | The effect of liver enzymes on adiposity: a Mendelian randomization study |
| Q89655513 | The effect of liver enzymes on body composition: A Mendelian randomization study |
| Q47595591 | The effect of low volume sprint interval training in patients with non-alcoholic fatty liver disease |
| Q64890915 | The effects of ipragliflozin on the liver-to-spleen attenuation ratio as assessed by computed tomography and on alanine transaminase levels in Japanese patients with type 2 diabetes mellitus. |
| Q37552230 | The expression of thymosin β4 in chronic hepatitis B combined nonalcoholic fatty liver disease |
| Q37075210 | The impact of obstructive sleep apnea on nonalcoholic fatty liver disease in patients with severe obesity |
| Q38714560 | The intersection of nonalcoholic fatty liver disease and obesity |
| Q38789869 | The intestinal microbiome and paediatric liver disease |
| Q39499177 | The kielin/chordin-like protein KCP attenuates nonalcoholic fatty liver disease in mice |
| Q40595855 | The limitations of opportunistic epidemiology, pseudopod epidemiology |
| Q36974822 | The longitudinal effect of the aldehyde dehydrogenase 2*2 allele on the risk for nonalcoholic fatty liver disease |
| Q38659340 | The presence and severity of nonalcoholic steatohepatitis is associated with specific changes in circulating bile acids |
| Q51028245 | The preventive effect of sustained physical activity on incident nonalcoholic fatty liver disease. |
| Q91905612 | The protective effect and mechanism of the FXR agonist obeticholic acid via targeting gut microbiota in non-alcoholic fatty liver disease |
| Q90471745 | The risk of atrial fibrillation in patients with non-alcoholic fatty liver disease and a high hepatic fibrosis index |
| Q40610020 | The role of extended criteria donors in liver transplantation for nonalcoholic steatohepatitis |
| Q37424899 | The transcription cofactor CRTC1 protects from aberrant hepatic lipid accumulation |
| Q93147070 | Therapeutic Mechanisms of Herbal Medicines Against Insulin Resistance: A Review |
| Q92350884 | Thrombospondin-I is a critical modulator in non-alcoholic steatohepatitis (NASH) |
| Q39197964 | Time-restricted feeding improves insulin resistance and hepatic steatosis in a mouse model of postmenopausal obesity |
| Q38843484 | Tollip Deficiency Alters Atherosclerosis and Steatosis by Disrupting Lipophagy |
| Q33685907 | Total fecal microbiota transplantation alleviates high-fat diet-induced steatohepatitis in mice via beneficial regulation of gut microbiota |
| Q37622448 | Transcriptional coordination of hepatic autophagy by nutrient-sensing nuclear receptor PPARα and FXR. |
| Q33802278 | Treatment of Nonalcoholic Fatty Liver Disease (NAFLD) in patients with Type 2 Diabetes Mellitus |
| Q26775632 | Treatment of Nonalcoholic Fatty Liver Disease: The Role of Medical, Surgical, and Endoscopic Weight Loss |
| Q30248230 | Treatment of nonalcoholic fatty liver disease: role of AMPK. |
| Q26751258 | Treatment of patients with type 2 diabetes and non-alcoholic fatty liver disease: current approaches and future directions |
| Q39177080 | Type 2 Diabetes and Hepatocellular Carcinoma: Risk Factors and Pathogenesis. |
| Q26752583 | Type 2 Diabetes in Non-Alcoholic Fatty Liver Disease and Hepatitis C Virus Infection--Liver: The "Musketeer" in the Spotlight |
| Q94411414 | ULSTER SOCIETY OF INTERNAL MEDICINE 94th (Autumn) MEETING, Friday 30th October 2015: Ulster Hospital Dundonald |
| Q100516145 | USP7 mediates pathological hepatic de novo lipogenesis through promoting stabilization and transcription of ZNF638 |
| Q94323706 | Ulster Society of Internal Medicine 95th (Spring) Meeting Friday 27th May 2016: Altnagelvin Hospital |
| Q98286823 | Ultrasound Attenuation Estimation in Harmonic Imaging for Robust Fatty Liver Detection |
| Q47128868 | Uncovering a Predictive Molecular Signature for the Onset of NASH-Related Fibrosis in a Translational NASH Mouse Model. |
| Q90418218 | Underlying nonalcoholic fatty liver disease is a significant factor for breast cancer recurrence after curative surgery |
| Q47132910 | Upregulation of miR-181a impairs hepatic glucose and lipid homeostasis. |
| Q38602520 | Ursodeoxycholic acid: effects on hepatic unfolded protein response, apoptosis and oxidative stress in morbidly obese patients. |
| Q90575091 | Use of Antiplatelet Agents Is Inversely Associated With Liver Fibrosis in Patients With Cardiovascular Disease |
| Q26748807 | Utilization of animal models to investigate non-alcoholic steatohepatitis-associated hepatocellular carcinoma |
| Q37634003 | Variables Associated With Inpatient and Outpatient Resource Utilization Among Medicare Beneficiaries With Nonalcoholic Fatty Liver Disease With or Without Cirrhosis |
| Q89014954 | Vegetarian diet, food substitution, and nonalcoholic fatty liver |
| Q41706825 | Vitamin D Is Associated with Severity and Mortality of Non-alcoholic Fatty Liver Disease: A US Population-based Study |
| Q37673981 | Vitamin D is Not Associated With Severity in NAFLD: Results of a Paired Clinical and Gene Expression Profile Analysis. |
| Q49212003 | Vitamin D levels do not predict the stage of hepatic fibrosis in patients with non-alcoholic fatty liver disease: A PRISMA compliant systematic review and meta-analysis of pooled data. |
| Q49367065 | Vitamin E as a Treatment for Nonalcoholic Fatty Liver Disease: Reality or Myth? |
| Q47569882 | Waist-to-hip ratio but not body mass index predicts liver cirrhosis in women |
| Q38291938 | XBP1s Is an Anti-lipogenic Protein |
| Q52884774 | [Autophagy in chronic liver diseases: a friend rather than a foe?] |
| Q52987727 | [Functional MR imaging of the liver]. |
| Q92152336 | [Role of lipophagy in the regulation of lipid metabolism and the molecular mechanism] |
| Q60961391 | miRNA Signature in NAFLD: A Turning Point for a Non-Invasive Diagnosis |
| Q50021100 | γδ T cells in liver diseases |
Search more.